Navigation Links
Oncolytic viruses mediating anti-tumor immunity in human cancer patients
Date:5/18/2010

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research. The therapy program is based on scientific research at the University of Helsinki and serves as the foundation for ongoing clinical development.

The results demonstrate an anti-tumor immunity of oncolytic viruses published for the first time in humans and indicate the strong efficacy of the next generation viruses against solid tumor cancers. As of today, 200 patients have been treated with oncolytic virus therapy in the company's Advanced Therapy Access Program.

"This is the first time it has been shown in humans that oncolytic viruses can be used for the induction of anti-tumor immunity. The GMCSF armed oncolytic adenovirus can mediate anti-tumor immunologic responses by recruiting natural killer cells and by the induction of tumor-specific cytotoxic T-cells", explains research professor Akseli Hemminki, the CSO and co-founder of Oncos.

"Anti-tumor immunity plays a major role in the strong efficacy results. We are starting clinical trials with CGTG-102, which is further improved compared of the virus described in this publication", comments Pekka Simula, the CEO and co-founder of Oncos.

The Cancer Research article reports strong safety and efficacy results in patients with advanced cancer progressing after available chemotherapy options. Out of the 15 radiologically evaluable patients 2 had complete responses (13%), 5 patients had stable disease (33 %) and 1 had a partial response (6 %). Therefore, the clinical benefit rate was 47% according to the RECIST criteria. Responses were frequently seen in both injected and non-injected tumors. The safety profile was favorable with no grade 4-5 side effects realized.

"It has been impressive to see
'/>"/>

Contact: Timo Ahopelto
timo.ahopelto@oncos.com
358-400-569-628
University of Helsinki
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
2. Mild-mannered metabolic helper rushes to fight invading viruses, researchers report
3. UBC graduate student finds a start/stop switch for retroviruses
4. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
5. Researchers find broad spectrum antiviral that fights multitude of viruses
6. Compound found that targets wide range of viruses
7. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
8. Poorly understood cell plays role in immunity against the flu
9. BHM Healthcare Congratulates PORT Human Services: First to Receive CABHA Status
10. The cost of medicalizing human conditions
11. It was brawn over beauty in human mating competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... PrettySkin4Less announces it is stocking up with ... top skin care manufacturer EMINENCE to meet customer demands. ... and active organic ingredients to promote actual change rather ... products offer. For this reason it’s not hard to ... like products that do what they say they will ...
(Date:6/19/2013)... 2013 Strict rules for ... Orriant is launching a new tool to help ... with regulations. New HHS regulations will soon ... if their employer offers outcome-based, health-contingent, compliant wellness ... with these standards for nearly a decade. Orriant ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... , TUESDAY, Dec. 14 (HealthDay News) -- ... genetic mutations associated with adrenal gland tumors by identifying ... affect the adrenal gland, which is located above the ... can also be cancerous -- cause the adrenal gland ...
... R.I. [Brown University] Brown University sociologists have ... about risky sexual behavior among Ethiopian teenagers and ... Simple, portable, low-cost, and low-tech, the group,s new ... and confidentially during face-to-face interviews. Professors of sociology ...
... Dec. 14 (HealthDay News) -- Two reports from the U.S. ... is hitting young and older Americans across the economic,spectrum. ... and Prevention, released the reports on Tuesday. Looking at ... data from 1988 to 1994 and from 2005 to 2008, ...
... Dec. 14, 2010 Cancer Research Institute, Inc. (CRI), ... the science of tumor immunology and foster the discovery ... the Cancer Vaccine Acceleration Fund (CVAF), a new model ... with the Ludwig Institute for Cancer Research Ltd (LICR) ...
... French . , MONTREAL, December 14, 2010 The ... learn to recognize the sound of their parents, voice and the ... parents and newborns admitted to the intensive care unit can be ... , Jan Lariviere, a nurse in the neonatal clinic and the ...
... Gardner HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay ... the most from health-care reform, a new report shows. ... the elimination of restrictions on people with preexisting conditions, while ... subsidized coverage through health insurance exchanges -- are slated for ...
Cached Medicine News:Health News:New survey device gets better information on teenage sexual behavior 2Health News:New survey device gets better information on teenage sexual behavior 3Health News:Obesity Rising Across All Income Levels: CDC 2Health News:Cancer Research Institute launches Cancer Vaccine Acceleration Fund 2Health News:Cancer Research Institute launches Cancer Vaccine Acceleration Fund 3Health News:Cancer Research Institute launches Cancer Vaccine Acceleration Fund 4Health News:Once upon a time in the Intensive Care Unit ... 2Health News:Report Finds Baby Boomers to Gain Most From Health Care Reform 2Health News:Report Finds Baby Boomers to Gain Most From Health Care Reform 3
(Date:6/19/2013)... 2013 The American Association for Homecare (AAHomecare), along ... , announced today the filing of a lawsuit ... , asking that the scheduled July 1 expansion of ... (DME) be stopped because of serious licensing irregularities. ... (HHS) Secretary Kathleen Sebelius as the defendant. ...
(Date:6/19/2013)... 19, 2013 Amgen is pleased to announce the ... , Canada and Puerto ... Amgen Award for Science Teaching Excellence (AASTE). Now in its ... through 12th grade level who have an outstanding ability to ... With a long-standing commitment to science education, Amgen established the ...
(Date:6/19/2013)... 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... England Journal of Medicine ( NEJM ) published ... investigational oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in ... lymphocytic lymphoma (SLL). Ibrutinib was shown to be safe ... even in patients who were at high-risk due to ...
Breaking Medicine Technology:AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 2Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6
... Texas and KOLN, Germany, June 8, 2011 Luminex ... der Stadt Koln, Institute of Pathology and Institute for ... Pathogen Panel (GPP) is being used successfully as a ... suspected of having an E. coli infection.  This includes ...
... Company (NYSE: LLY ) today announced that ... California ruled in Lilly,s favor, vacating a temporary restraining ... a preliminary injunction that sought to impose restrictions on ... recently filed litigation involving the two companies, diabetes collaboration ...
Cached Medicine Technology:Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis 2Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis 3Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis 4U.S. District Court Rules in Favor of Lilly in Amylin Litigation 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: